ClinicalTrialsFinder
RecruitingPhase 1Phase 2NCT06087458

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non- Neovascular Age-Related Macular Degeneration

Sponsor

Perceive Biotherapeutics, Inc.

Enrollment

60 participants

Start Date

Jun 21, 2023

Study Type

INTERVENTIONAL

Conditions

Geographic AtrophyAge-Related Macular DegenerationNon-neovascular AMD

Summary

The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.

Eligibility

Min Age: 60 Years

Inclusion Criteria7

  • Are ≥60 years of age at the time of consent.
  • Are willing and able to understand and provide written informed consent.
  • Are willing and able to return for scheduled treatment and follow-up examinations.
  • Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
  • Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.
  • Absence of signs of non-exudative MNV.
  • Meet certain genotype criteria for risk of AMD.

Exclusion Criteria1

  • Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.
Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALVOY-101

VOY-101

Locations(11)

Retina Macula Institute of AZ

Scottsdale, Arizona, United States

The Retina Partners

Encino, California, United States

Retinal Consultants Medical Group

Sacramento, California, United States

Retina Consultants San Diego

San Diego, California, United States

Star Retina

Burleson, Texas, United States

Retina Center of Texas

Southlake, Texas, United States

University of Utah John A. Moran Eye Center

Salt Lake City, Utah, United States

Sydney Retina Clinic and Day Surgery

Sydney, New South Wales, Australia

Cerulea Clinical Trials

East Melbourne, Victoria, Australia

Rambam Medical Center

Haifa, Israel

Tel-Aviv Sourasky Medical Center, Ophthalmology Division

Tel Aviv, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06087458

Related Trials

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT0696137016 locations

National Eye Institute Biorepository for Retinal Diseases

NCT014966251 location

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

NCT0692402114 locations

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

NCT0562611417 locations

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT0721523413 locations